Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · SEI

MetLife Small Company Equity Fund Institutional Shares (MSVIX)

Ticker MSVIX · · Holdings as of Jun 30, 2026

Expense ratio
0.99%$99/yr per $10k
5-yr return
+11.0%annualized
1-yr return
+9.0%as of Dec 2025
Net assets
$7.9Mall share classes
Holdings
78

Bottom line

Is MSVIX a good fund? The bottom line

MSVIX is the Institutional share class of MetLife Small Company Equity Fund, a managed small-cap mutual fund from SEI.

Its expense ratio is 0.99% — about $99 a year on every $10,000 invested, more expensive than 51% of small-cap funds we track.

It returned +9.0% over one year, +11.0% a year over five years (as of Dec 31, 2025, per its prospectus).

With $7.9 million in net assets and 78 holdings, its largest position is N/a (3.7%) and the top 10 make up 19.7% of the portfolio.

What stands out

  • 5-year return beat 90% of category peers

What to watch

  • Small fund ($7.9 million) — small funds are likelier to close

Updated Nov 19, 2026

What MSVIX invests in

The MetLife Small Company Equity Fund (the Small Company Equity Fund or the Fund) seeks to provide long-term capital appreciation with less volatility than the U.S. small company market.

Under normal circumstances, the Fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of small companies. This investment policy may be changed by the Fund upon 60 days prior written notice to shareholders. For purposes of the Funds 80% policy, equity securities include common stocks and exchange-traded funds (ETFs) with economic characteristics similar to equity securities. The Fund considers small companies to be those with market capitalizations within the range of the market capitalizations of companies in the Russell 2500 Index at the time of purchase, and ETFs that aim to replicate or produce returns that generally correspond to small company indexes. The market capitalization range of the Russell 2500 Index was approximately $24 million to $32.5 billion as of September 30, 2025, and may change over time. At any given time…

From the fund's prospectus (filed Jan 28, 2026).

MSVIX performance

Fund calendar-year total returns, 2019–2025 2019: +23.0%; 2020: +6.7%; 2021: +26.5%; 2022: −4.9%; 2023: +12.2%; 2024: +14.4%; 2025: +9.0% +23.0% 2019 +6.7% 2020 +26.5% 2021 −4.9% 2022 +12.2% 2023 +14.4% 2024 +9.0% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
MSVIX+9.0%+11.0%—
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full MSVIX performance history →

What MSVIX costs

On a $10,000 investment, MSVIX's 0.99% expense ratio costs about $99 a year. The prospectus estimates $2,487 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full MSVIX fee table →

MSVIX top 10 holdings

#Holding% of fund
1N/a3.67%
2Halozyme Therapeutics, Inc.1.99%
3Kontoor Brands, Inc.1.99%
4SPDR Series Trust - SPDR S&P Biotech ETF1.88%
5Advanced Energy Industries, Inc.1.85%
6Praxis Precision Medicines Inc1.75%
7iShares Russell 2000 ETF1.72%
8Zions Bancorporation, National Association1.66%
9Gates Industrial Corporation Plc1.64%
10Standardaero, Inc.1.60%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 19.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to MSVIX

More funds like MSVIX →

MSVIX FAQ

What is the expense ratio of MSVIX?
MSVIX's expense ratio is 0.99%, which works out to about $99 a year for every $10,000 invested. The prospectus estimates total costs of $2,487 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MSVIX a good investment?
It depends on your goals, but the data points to: 5-year return beat 90% of category peers; small fund ($7.9 million) — small funds are likelier to close. This is general information, not personalized advice.
What does MSVIX hold?
MSVIX's largest holdings are N/a (3.7%), Halozyme Therapeutics, Inc. (2.0%), Kontoor Brands, Inc. (2.0%), SPDR Series Trust - SPDR S&P Biotech ETF (1.9%), Advanced Energy Industries, Inc. (1.9%). It holds 78 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MSVIX's 5-year return?
MSVIX returned +11.0% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages MSVIX?
MSVIX is offered by SEI through Advisors' Inner Circle Fund III.